Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients.
(2015) In PLoS ONE 10(5).- Abstract
- Myeloid-derived suppressor cells (MDSCs) are highly immunosuppressive myeloid cells, which increase in cancer patients. The molecular mechanism behind their generation and function is unclear. Whereas granulocytic-MDSCs correlate with poor overall survival in breast cancer, the presence and relevance of monocytic-MDSCs (Mo-MDSCs) is unknown. Here we report for the first time an enrichment of functional blood Mo-MDSCs in breast cancer patients before they acquire a typical Mo-MDSC surface phenotype. A clear population of Mo-MDSCs with the typical cell surface phenotype (CD14+HLA-DRlow/-CD86low/-CD80low/-CD163low/-) increased significantly first during disease progression and correlated to metastasis to lymph nodes and visceral organs.... (More)
- Myeloid-derived suppressor cells (MDSCs) are highly immunosuppressive myeloid cells, which increase in cancer patients. The molecular mechanism behind their generation and function is unclear. Whereas granulocytic-MDSCs correlate with poor overall survival in breast cancer, the presence and relevance of monocytic-MDSCs (Mo-MDSCs) is unknown. Here we report for the first time an enrichment of functional blood Mo-MDSCs in breast cancer patients before they acquire a typical Mo-MDSC surface phenotype. A clear population of Mo-MDSCs with the typical cell surface phenotype (CD14+HLA-DRlow/-CD86low/-CD80low/-CD163low/-) increased significantly first during disease progression and correlated to metastasis to lymph nodes and visceral organs. Furthermore, monocytes, comprising the Mo-MDSC population, from patients with metastatic breast cancer resemble the reprogrammed immunosuppressive monocytes in patients with severe infections, both by their surface and functional phenotype but also at their molecular gene expression profile. Our data suggest that monitoring the Mo-MDSC levels in breast cancer patients may represent a novel and simple biomarker for assessing disease progression. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5448534
- author
- organization
-
- Breast Cancer Surgery (research group)
- The Liquid Biopsy and Tumor Progression in Breast Cancer (research group)
- Cancer Immunology, Malmö (research group)
- Experimental Infection Medicine, Malmö (research group)
- Breastcancer-genetics
- Division of Translational Cancer Research
- Paediatrics (Lund)
- Tumor microenvironment
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
- Infectious Diseases Research Unit (research group)
- Clinical Microbiology, Malmö (research group)
- Surgery (Lund)
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- PLoS ONE
- volume
- 10
- issue
- 5
- article number
- e0127028
- publisher
- Public Library of Science (PLoS)
- external identifiers
-
- pmid:25992611
- wos:000354921400091
- scopus:84930621644
- pmid:25992611
- ISSN
- 1932-6203
- DOI
- 10.1371/journal.pone.0127028
- project
- CTC-MBC, Circulating Tumor Cells in Metastatic Breast Cancer
- Breast Cancer Surgery
- language
- English
- LU publication?
- yes
- id
- 557e9681-18b2-4809-927e-64e1da98217d (old id 5448534)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25992611?dopt=Abstract
- date added to LUP
- 2016-04-01 15:01:13
- date last changed
- 2023-12-12 13:03:42
@article{557e9681-18b2-4809-927e-64e1da98217d, abstract = {{Myeloid-derived suppressor cells (MDSCs) are highly immunosuppressive myeloid cells, which increase in cancer patients. The molecular mechanism behind their generation and function is unclear. Whereas granulocytic-MDSCs correlate with poor overall survival in breast cancer, the presence and relevance of monocytic-MDSCs (Mo-MDSCs) is unknown. Here we report for the first time an enrichment of functional blood Mo-MDSCs in breast cancer patients before they acquire a typical Mo-MDSC surface phenotype. A clear population of Mo-MDSCs with the typical cell surface phenotype (CD14+HLA-DRlow/-CD86low/-CD80low/-CD163low/-) increased significantly first during disease progression and correlated to metastasis to lymph nodes and visceral organs. Furthermore, monocytes, comprising the Mo-MDSC population, from patients with metastatic breast cancer resemble the reprogrammed immunosuppressive monocytes in patients with severe infections, both by their surface and functional phenotype but also at their molecular gene expression profile. Our data suggest that monitoring the Mo-MDSC levels in breast cancer patients may represent a novel and simple biomarker for assessing disease progression.}}, author = {{Bergenfelz, Caroline and Larsson, Anna-Maria and von Stedingk, Kristoffer and Gruvberger, Sofia and Aaltonen, Kristina and Jansson, Sara and Jernström, Helena and Janols, Helena and Wullt, Marlene and Bredberg, Anders and Rydén, Lisa and Leandersson, Karin}}, issn = {{1932-6203}}, language = {{eng}}, number = {{5}}, publisher = {{Public Library of Science (PLoS)}}, series = {{PLoS ONE}}, title = {{Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients.}}, url = {{https://lup.lub.lu.se/search/files/4302117/8516405.pdf}}, doi = {{10.1371/journal.pone.0127028}}, volume = {{10}}, year = {{2015}}, }